Prostate Cancer

  • Author: Gary R. MacVicar, MD (More Info)
  • Editor in Chief: Ramaswamy Govindan, MD
  • Last Reviewed: 8/9/18 (What's New)

Summary

  • CRPC defined as cancer progression in the presence of castrate levels of testosterone[Chen 2012]
  • Both apalutamide and enzalutamide are approved by the FDA for nonmetastatic CRPC based on prolonged metastasis-free survival in clinical trials
  • Treatment options for metastatic CRPC include: abiraterone acetate, cabazitaxel, docetaxel, enzalutamide, radium-223, sipuleucel-T (Table 7)
  • Initial Therapy for Asymptomatic/Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
      Sipuleucel-T
        Abiraterone
          Enzalutamide
          Symptomatic Metastatic Castration-Resistant Prostate Cancer
            Radium-223
            Therapy Following Progression on Docetaxel
              Abiraterone After Docetaxel
                Enzalutamide After Docetaxel
                  Cabazitaxel
                    Other Treatment Settings

                  Action required